Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
复制标题
铂和米托蒽醌治疗转移性前列腺癌的 II 期研究:西南肿瘤小组研究。
DOI:
10.1016/s0959-8049(05)80080-2
复制
发表时间:
1992
期刊:
影响因子:
--
通讯作者:
Larrimer,NR
中科院分区:
文献类型:
--
作者:
Osborne,CK;Blumenstein,BA;Crawford,ED;Weiss,GR;Bukowski,RM;Larrimer,NR
44 eligible patients with measurable or evaluable metastatic prostate cancer were treated with monthly cycles of cisplatin and mitoxantrone. Good-risk patients received cisplatin 60 mg/m2intravenously and mitoxantrone 10 mg/m2intravenously every 4 weeks. The dose in poor-risk patients (elderly or white blood cell count < 4000/μl, 4 × 109/1, or extensive prior radiation) was reduced to 8 mg/m2. Toxicity was manageable and consisted primarily of myelosuppression. There were no complete responses and the partial response rate was only 12%. Median progression-free survival was 2.7 months for measurable and 4.1 months for evaluable disease patients. Median survivals were 4.9 and 8.7 months, respectively. This combination has minimal activity in hormone refractory metastatic prostate cancer.
登录
查看更多内容
DOI:
10.1016/s0022-5347(17)51917-5
发表时间:
1983
期刊:
The Journal of urology
影响因子:
--
作者:
M. Soloway;S. Beckley;M. Brady;T. Chu;J. Dekernion;C. Dhabuwala;J. Gaeta;R. Gibbons;S. Loening;C. McKiel;D. Mcleod;J. Pontes;G. Prout;P. Scardino;J. Schlegel;Joseph D. Schmidt;W. Scott;N. Slack;G. Murphy
通讯作者:
G. Murphy
影响因子:
11.8
作者:
F. Schabel;T. Corbett;D. Griswold;W. R. Laster;M. W. Trader
通讯作者:
M. W. Trader
DOI:
10.1016/s0022-5347(17)57535-7
发表时间:
1978
期刊:
The Journal of urology
影响因子:
--
作者:
C. Merrin
通讯作者:
C. Merrin
DOI:
--
发表时间:
1983
期刊:
Cancer treatment reports
影响因子:
--
作者:
Osborne,CK;Drelichman,A;VonHoff,DD;Crawford,ED
通讯作者:
Crawford,ED
影响因子:
39.2
作者:
F. Torti;S. Carter
通讯作者:
S. Carter